Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Nonradiographic Axial Spondyloarthritis
NCT02407223Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of ustekinumab in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: terminated.
02
Drugs
ustekinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02407223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407223.